An observational study in Congenital Uterine Anomaly, sponsored by Yale University. Recruiting at 1 site in United States. Open to female participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Yale University · Observational
The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.
Aim 1: To identify female subjects diagnosed with a Congenital Uterine Anomaly (CUA) receiving care at Yale New Haven Health.
Aim 2: Identify (i) the prevalence of renal, breast, ovarian, uterine and vaginal cancers associated with CUAs, and (ii) the association of environmental factors, via a survey obtained by phone, email or interview.
Aim 3: Conduct genetic evaluation of the index subjects, parents, sister(s) (as feasible), and female offspring to identify potential causes and patterns of inheritance using whole exome sequencing (WES) and microarray.
Following informed consent, blood will be collected for genetic evaluation. DNA will be extracted from EDTA-blood and analyzed using an integrated approach of microarray for copy number variations (CNV), and Whole Exome Sequencing (WES) for Single Nucleotide Variation (SNV).
Undertaking review of the medical records will identify the cohort of patients we wish to survey to then ascertain further information regarding their CUA diagnosis and other related details. The information to be elicited from the survey are outlined in the attached survey questions. Key associations we seek to investigate include (1) the type and prevalence of renal, breast, ovarian, uterine and vaginal cancers among patients with Mullerian Anomaly, and (2) identifying potential in-utero exposure to particular environmental agents in patients with CUAs.
Review of the medical records will enable us to undertake this first key step of establishing a cohort of subjects with MA and an initial data set related to their specific health information. We anticipate further investigations may build upon this initial data set, both with the cohort established, and more broadly with collaborators and additional national and international cohorts of patients with MA.
Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.
Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women and girls who have received care within the Yale New Haven Health system and have a CUA diagnosis Anticipated number - approximately 300 subjects Age range - from 13 years old and older Health status - able to participate in consent and assent (based on age) process
Exclusion Criteria:
The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
Prevalence of breast cancer in women with CUA's compared to women without CUA's
Prevalence of breast cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6-months
Prevalence of ovarian cancer in women with CUA's compared to women without CUA's
Prevalence of ovarian cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6-months
Prevalence of uterine cancer in women with CUA's compared to women without CUA's
Prevalence of uterine cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6-months
Prevalence of cervical cancer in women with CUA's compared to women without CUA's
Prevalence of cervical cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6 month
Prevalence of vaginal cancer in women with CUA's compared to women without CUA's
Prevalence of vaginal cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6 month
Prevalence of renal cancer in women with CUA's compared to women without CUA's
Prevalence of renal cancer in women with CUA's compared to women without CUA's will be measured
Time frame: 6 month
Whole exome sequencing (WES) and microarray
WES and microarray will be conducted in subjects with CUAs. The discovery of possible causative genes would be measured using yes/no outcome variable.
Time frame: 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uterine Anomalies
Yale University